{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.0","upperLimit":"15.2","value":"2.79"},{"groupId":"OG001","lowerLimit":"1.0","upperLimit":"2.2","value":"1.41"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"description":"TTCR is defined from JCARH125 infusion to the first document of stringent complete response (sCR) or complete response (CR).\n\nsCR=complete response plus normal free light chain ratio and absence of clonal cells in bone marrow biopsy by immunohistochemistry; CR=negative immunofixation of serum and urine and disappearance of any soft tissue plasmacytomas and \\< 5% plasma cells in bone marrow aspirates.\n\nProgressive disease is defined as (1) Increase of ≥25% from lowest confirmed response; (2) Appearance of a new lesion(s); (3) ≥50% increase in circulating plasma cells.","dispersionType":"Full Range","groups":[{"description":"JCARH125 IV at dose level 600 x 10\\^6 consisting of CD3+CAR+T cells expansion","id":"OG000","title":"Phase 2 600 x 10^6 Cells"},{"description":"JCARH125 IV at dose level 600 x 10\\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy","id":"OG001","title":"Phase 2a 600 x 10^6 Cells Anti-BCMA"}],"paramType":"MEDIAN","populationDescription":"All participants with sCR or CR who received conforming JCARH125 cell product at the recommended phase 2 dose and have measurable disease at the last disease assessment prior to receiving JCARH125 infusion in phase 2 and in phase 2a","reportingStatus":"POSTED","timeFrame":"Form date of first infusion to the date of disease progression, or death, due to any reason (Up to approximately 61 months)","title":"Time to Complete Response (TTCR) in Phase 2 and Phase 2a","type":"SECONDARY","unitOfMeasure":"Months"}